Oncology

At the Smilow Cancer Hospital, oncology pharmacists play an important role in the delivery of care for patients with cancer.

Despite an ongoing long-term debate, no link was found between cancer and the use of ACE inhibitors, beta blockers, and other common antihypertensive drugs.

A recent study demonstrated the safety and clinical activity of E7 TCR-T cells in the treatment of highly refractory metastatic HPV- 16+ cancers.

Oral chemotherapy may be an important option for patients during the COVID-19 pandemic, as it would allow them to receive treatment at home.

Study results have demonstrated that pharmacists are effective partners in improving care, reducing cost, and avoiding drug complications for patients with cancer.

Current advances in the analysis of the mutational status of different genes are providing investigators insights into new treatment pathways that can improve outcomes for patients.

Women who typically have a better prognosis in the primary breast cancer setting experienced worse survival after a second primary breast cancer.

Despite improvements in the understanding and treatment of chemotherapy-induced nausea and vomiting (CINV), nausea and emesis continue to be a distressing adverse event for patients.

Targeted photodynamic therapy has garnered increasing attention… because of its ability to treat tumors without surgery, chemotherapy, or radiation.

A new medication for certain rare blood cancers has now become available through a limited distribution with AllianceRx Walgreens Prime.

Pharmacists should refer patients to a health care provider if any symptoms could be indicative of a GIST.

Challenges and impact of rare diseases are faced by pharmacy stakeholders.

The FDA has approved a liquid biopsy test for all solid tumors with multiple companion diagnostic indications, including for rucaparib tablets.

Targeted radiotherapy amounted to fewer deaths over a 5-year follow-up period among patients with breast cancer.

Researchers have found that gene expression associated with aging was higher in young cancer survivors who are frail and in young patients with cancer following their treatment with chemotherapy.

Patient assistance programs are often the difference between accessing the drug and increasing abandonment rate.

PTCE, the industry-leading continuing pharmacy education provider, becomes sole provider for association’s 3 major meetings through 2021.

In addition to clinical procedures, some support groups for patients with breast cancer were also canceled as a result of the COVID-19 pandemic.

The increasing prevalence of oral oncolytics use, further accelerated by COVID-19, heightens the need for strong patient-pharmacist treatment coordination.

The researchers found that an ILI aimed at weight loss lowered incidence of obesity-related cancers by 16% in adults with overweight or obesity and T2D

Most women with breast cancer receive treatment post surgery, such as chemotherapy, hormone therapy, and radiation. Targeted therapy is useful against cancers that have spread to distant parts of the body.

An online survey found that 44% of breast cancer survivors had care delayed during the COVID-19 pandemic.

Following the expansion of Medicaid coverage under the Affordable Care Act, individuals with low income are less likely to be diagnosed with advanced cancer.

The new analysis of the 23-year follow-up results of the trial found that screening women between 40 and 49 years of age led to a substantial and significant 25% reduction in breast cancer mortality in the first 10 years.

By their training, pharmacists are natural problem solvers, and our education has taught us how to use resources to find an answer and often a solution. The world is waiting for a pharmaceutical solution to coronavirus disease 2019 (COVID-19).

Because triple-negative breast cancer does not express receptors involved in most breast cancers, the investigative therapy could offer a much-needed option.

The mortality rates for complex cancer procedures was shown to differ significantly depending on whether the procedure took place at 1-star hospitals or 5-star hospitals.

Medical oncologists globally should not discontinue or delay anti-cancer treatment that may potentially impact overall survival during the COVID-19 pandemic.